Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Pasi A. Jänne, Yasuhito Fujisaka et al.|Science Translational Medicine|2011Cited by 670
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)John Souglakos, Vassilis Georgoulias|British Journal of Cancer|2006Cited by 402
IGF-I and IGF-II in relation to colorectal cancerOrestis Manousos, Christos S. Mantzoros, John Souglakos et al.|International Journal of Cancer|1999Cited by 193
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupKaitlyn K.H. Goey, Miriam Koopman, Halfdan Sørbye et al.|European Journal of Cancer|2018Cited by 34
Federated Deep Learning Enables Cancer Subtyping by ProteomicsZhaoxiang Cai, Alexander Swarbrick, Emma L. Boys et al.|Cancer Discovery|2025Cited by 9